Yondelis® revenues totalled 19.8 million euro, the highest quarterly figure since marketing of the drug began.
Group EBITDA amounted to 9.5 million euro, following a 19% increase in R&D expenditure, which reflects the clinical progress with the pipeline.
Madrid, 27 April 2015:
Net sales in the biopharmaceutical sector amounted to 21.1 million euro (vs. 20.9 million euro in 1Q14). Within that figure, Yondelis® accounted for 19.8 million euro (vs. 19.7 million euro in 1Q14), the drug's best quarterly sales figure since it reached the market.
Net sales of consumer chemicals in the first quarter totalled 13.6 million euro, an increase of 4% with respect to the same period last year, due to the gradual recovery in demand in Spain, which may herald a change in trend in the domestic market.
Zeltia's other operating revenues (which include revenues from licensing agreements, such as milestone payments, as well as royalties and subsidies) totalled 11.1 million euro, compared with 18.9 million euro in 1Q14.
During 1Q15, the group also collected a 10 million dollar milestone payment under an agreement signed with Janssen Products LP in 2011. The milestone payment in
2014 was 25 million dollars.
As a result, group EBITDA in 1Q15 amounted to 9.5 million euro, compared with
19.4 million euro in 1Q14. The company expects to receive additional payments this year for reaching various milestones as set out in licensing contracts with partners Janssen Products LP and Taiho Pharmaceuticals. These milestones are related to the approval of sales authorisation dossiers that our partners have submitted to their respective regulatory authorities in the US and Japan. Attributable income amounted to 6.5 million euro, compared with 16.9 million euro in 1Q14.